Drug Information

Drug General Information
Drug ID
D0V1WQ
Former ID
DNCL002926
Drug Name
TAK-875
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 3 [523927], [541618]
Company
Takeda Pharmaceuticals U.S.A.
Structure
Download
2D MOL

3D MOL
Formula
C29H32O7S
InChI
InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
InChIKey
BZCALJIHZVNMGJ-HSZRJFAPSA-N
PubChem Compound ID
24857286
PubChem Substance ID
50088191, 57154181, 134464228, 135268194, 136349531, 136367662, 140817135, 143499812, 152233038, 152258229, 160647065, 160865873, 162011413, 162202766, 164044689, 170501170, 172232430, 172919610, 174006778, 174525708, 174526154, 178103098, 185967135, 191112353, 196409677, 198984389, 203355926, 223375341, 224346112, 226560798, 242587051, 245772988, 249735423, 252110185, 252151428, 252216368, 252450486, 252810271
Target and Pathway
Target(s) GPR40 Target Info Modulator [533183]
KEGG Pathway Insulin secretion
Reactome G alpha (q) signalling events
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
WikiPathways GPCRs, Class A Rhodopsin-like
Incretin Synthesis, Secretion, and Inactivation
Gastrin-CREB signalling pathway via PKC and MAPK
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 523927ClinicalTrials.gov (NCT01609582) Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease. U.S. National Institutes of Health.
Ref 541618(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6484).
Ref 533183Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.